There is one clinical trial.
The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research has been done since the FDA determination to further support the use of the device outside of its current labeling.
Description: Volume of IV fluid infused during treatmentMeasure: Volume of IV fluid infused Time: 1 year
Description: Amount of blood pressure medication utilized during treatmentMeasure: Quantity of Blood pressure medication administered Time: 1 year
Description: Categorical determination of resuscitation status as over- or under- resuscitatedMeasure: Resuscitation status Time: 1 year
Description: FiO2 levels administeredMeasure: FiO2 needs Time: 1 year
Description: Days spent on oxygenMeasure: Days on Oxygen Time: 1 year
Description: Number of participants with hospital acquired pneumoniaMeasure: Number of participants with hospital acquired pneumonia Time: 1 year
Description: Number of patients who acquire an acute kidney injuryMeasure: Number of Patients with Acute Kidney Injury (AKI) Time: 1 year
Description: Number of patients who experience hemodynamic collapse defined as drop in systolic blood pressure below 80mm HgMeasure: Number of patients with hemodynamic collapse Time: 1 year
Description: Number of patients who experience mortalityMeasure: mortality Time: 1 year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports